QL-1200186

• UNSPSC Description:

  QL-1200186 is anorally activeand selective inhibitor ofTYK2. Oral administration of QL-1200186, dose-dependently inhibitsinterferon-γ(IFNγ) production afterinterleukin-12(IL-12) challenge and significantly ameliorates skin lesions in psoriatic mice[1].

• Target Antigen:

  JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ql-1200186.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  COC(C(C(C=C1)=NN1C)=CC(CCOCC2=NC3=CC=C2)=C4)=C4NC(C=C(N3)N=C5)=C5C(NC)=O

• Molecular Weight:

  485.54

• References & Citations:

  [1]Chen CX, et al. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways. Cell Commun Signal. 2023;21(1):287. Published 2023 Oct 16.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2848664-42-4